Kelly Chin, Richard Channick

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations


Bosentan (Tracleer®, Actelion Pharmaceuticals Ltd) is an oral dual endothelin receptor antagonist approved for use in functional class III to IV pulmonary arterial hypertension. In two placebo-controlled trials, patients receiving bosentan showed improved functional class, 6-minute walk distance and hemodynamics over a 12- to 16-week period. Follow-up data over 3 years has shown few deteriorations, with the majority of patients maintaining their response to bosentan alone. Investigations exploring the use of bosentan as an add-on agent to intravenous epoprostenol (Flolan®, GlaxoSmithKline Plc) in those with the most severe disease are ongoing. Bosentan may also have antifibrotic properties and its use in pulmonary fibrosis is being explored. Ease of administration of bosentan with twice-daily oral dosing will provide many patients with pulmonary hypertension an option for treatment without the risks and discomforts of continuous intravenous medication.

Original languageEnglish (US)
Pages (from-to)175-182
Number of pages8
JournalExpert Review of Cardiovascular Therapy
Issue number2
StatePublished - Mar 2004


  • Bosentran
  • Endothelin antagonists
  • Pulmonary arterial hypertension

ASJC Scopus subject areas

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Bosentan'. Together they form a unique fingerprint.

Cite this